TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from HLS Therapeutics Inc ( (TSE:HLS) ) is now available.
HLS Therapeutics Inc. announced that Health Canada has approved NILEMDO® for the reduction of LDL-cholesterol in Canadians at risk of cardiovascular disease. This approval, supported by data from the CLEAR Outcomes trial, strengthens HLS’s position as a leading cardiovascular company in Canada and is expected to significantly impact its future growth. The commercial launch of NILEMDO is planned for Q2 2026. However, HLS received a Notice of Non-Compliance for NEXLIZET®, requiring additional information for approval, although no concerns were raised about its clinical data, efficacy, or safety.
The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$4.00 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.
Spark’s Take on TSE:HLS Stock
According to Spark, TipRanks’ AI Analyst, TSE:HLS is a Neutral.
HLS Therapeutics Inc. faces significant challenges in financial performance, particularly in revenue growth and profitability, which are reflected in its negative P/E ratio. Technical analysis indicates bearish momentum, further impacting the stock’s outlook. While there are positive aspects such as strong gross margins and cash flow management, these are overshadowed by the company’s current struggles.
To see Spark’s full report on TSE:HLS stock, click here.
More about HLS Therapeutics Inc
HLS Therapeutics Inc. is a pharmaceutical company formed in 2015, focusing on the acquisition and commercialization of late-stage development, commercial stage promoted, and established branded pharmaceutical products. The company primarily addresses unmet needs in the treatment of psychiatric disorders and cardiovascular disease, with a market focus on Canada.
Average Trading Volume: 16,462
Technical Sentiment Signal: Hold
Current Market Cap: C$154.8M
For detailed information about HLS stock, go to TipRanks’ Stock Analysis page.